1. Abekawa, T., Ohmori, T., & Koyama, T. (1994). Effects of repeated administration of a high dose of methamphetamine on dopamine and glutamate release in rat striatum and nucleus accumbens. Brain Research, 643, 276–281.
2. Alam, M., & Schmidt, W. J. (2004). Mitochondrial complex I inhibition depletes plasma testosterone in the rotenone model of Parkinson’s disease. Physiology and Behavior, 83, 395–400.
3. Andrews, A. M., Ladenheim, B., Epstein, C. J., Cadet, J. L., & Murphy, D. L. (1996). Transgenic mice with high levels of superoxide dismutase activity are protected from the neurotoxic effects of 2′-NH 2-MPTP on serotonergic and noradrenergic nerve terminals. Molecular Pharmacology, 50, 1511–1519.
4. Andrews, A. M., & Murphy, D. L. (1993a). Sustained depletion of cortical and hippocampal serotonin and norepinephrine but not striatal dopamine by 1-methyl-4-(2′-aminophenyl)-1,2,3,6-tetrahydropyridine (2′-NH2-MPTP): a comparative study with 2′-CH 3-MPTP and MPTP. Journal of Neurochemistry, 60, 1167–1170.
5. Andrews, A. M., & Murphy, D. L. (1993b). 2′-NH 2-MPTP in Swiss Webster mice: evidence for long-term (6-month) depletions in cortical and hippocampal serotonin and norepinephrine, differential protection by selective uptake inhibitors or clorgyline and functional changes in central serotonin neurotransmission. Journal of Pharmacology and Experimental Therapeutics, 267, 1432–1439.